Startups
2006
CHEMOTARGETS SL
Dirección
Carrer de Baldiri Reixac 15, 08028 Barcelona, España
Propiedad de CERCA
Barcelona, Spain
1992
Hospital del Mar Research Institute (HMRIB)
Contacto del Centro CERCA
IÁ
Ismael Ávila
Hospital del Mar Research Institute (HMRIB)Estado
Estado de la empresaEstado actual de la empresa
Área DeepTech
Descripción
Descripción
Chemotargets ofrece metodologías computacionales validadas y de vanguardia con un rendimiento predictivo de primer orden en el mercado. La estrategia de innovación de la empresa está impulsada por los nuevos métodos generados en el laboratorio del Dr. Mestres. El objetivo de Chemotargets es ayudar a la industria biofarmacéutica a acelerar el proceso de comercialización de nuevos medicamentos, acelerando los programas de descubrimiento y desarrollo de fármacos y mejorando la rentabilidad y la seguridad. Actualmente, Chemotargets es reconocida como líder mundial en soluciones de análisis predictivo para empresas farmacéuticas y biotecnológicas e instituciones de investigación. Desde mayo de 2017, Prous Institute for Biomedical Research realiza una inversión estratégica en Chemotargets SL que permite acelerar el desarrollo de productos CLARITYⓇ.
Descripción del producto
Chemotargets CLARITY® is an innovative data science solution that fully exploits the synergies between known experimental results and predicted insights to discover hidden knowledge, untap new competitive opportunities and improve R&D efficiencies.
CLARITYⓇ enables global profiling for a given molecule or set:
Quantitative binding and functional activity for mechanisms of action associated with therapeutic activities and safety liabilities (PHARMACOLOGY and SAFETY).
Predicted metabolites and their pharmacological profiles, and comparison with substrates (METABOLISM).
CLARITYⓇ ‘s engine uses:
An expertly curated training set of 2.6 million compounds data derived from patents, journals and public databases to ensure comprehensive coverage of the chemical space pharmacology, and covers related drug safety information available.
Multiple integrated state-of-the-art computational methods to ensure high level of confidence.
- Predicted target affinities with 6 independent approaches
- Predicted safety associations with 4 independent approaches
- Consensus confidence scores provided for each predicted interaction
- Prediction of metabolites, using a manually curated training dataset of experimental biotransformations in xenobiotics, including both Phase I and II metabolic reactions, extracted from the literature
- Comparative pharmacology between substrate and metabolites
- Coverage of a broad range of target-actions essential for secondary pharmacology profiling and provides information on the adverse effects linked to these mechanisms of action
- Improved analytics and visualisation tools that allow direct access to known data, both internal (if integrated) and external, and fast generation of predicted data
- Advanced Interpretation tools
CLARITYⓇ enables global profiling for a given molecule or set:
Quantitative binding and functional activity for mechanisms of action associated with therapeutic activities and safety liabilities (PHARMACOLOGY and SAFETY).
Predicted metabolites and their pharmacological profiles, and comparison with substrates (METABOLISM).
CLARITYⓇ ‘s engine uses:
An expertly curated training set of 2.6 million compounds data derived from patents, journals and public databases to ensure comprehensive coverage of the chemical space pharmacology, and covers related drug safety information available.
Multiple integrated state-of-the-art computational methods to ensure high level of confidence.
- Predicted target affinities with 6 independent approaches
- Predicted safety associations with 4 independent approaches
- Consensus confidence scores provided for each predicted interaction
- Prediction of metabolites, using a manually curated training dataset of experimental biotransformations in xenobiotics, including both Phase I and II metabolic reactions, extracted from the literature
- Comparative pharmacology between substrate and metabolites
- Coverage of a broad range of target-actions essential for secondary pharmacology profiling and provides information on the adverse effects linked to these mechanisms of action
- Improved analytics and visualisation tools that allow direct access to known data, both internal (if integrated) and external, and fast generation of predicted data
- Advanced Interpretation tools